Abstract:Background More than 80% of individuals with multiple sclerosis (MS) experience a relapsing-remitting disease course. Approximately ten years after disease onset, an estimated 50% of individuals with relapsing-remitting MS (RR-MS) convert to secondary progressive MS. Quality of life is considerably impaired in early RR-MS. The increased costs are associated with relapse occurrence and increasing disease severity. Pharmaceutical interventions aimed at delaying the progression of disease may help to reduce the economic burden of MS. It has been showed that B lymphocytes involve in the pathophysiology of MS and rituximab lyses B cells via complement and antibody-dependent cellular cytotoxicity. Current clinical trials are evaluating the role of rituximab as a B-cell-targeted therapy in the treatment of RR-MS. Objectives The effectiveness and safety of rituximab alone or as add-on, versus placebo or other treatments for RR-MS were assessed. Search methods The Trials Search Co-ordinator searched the Cochrane Multiple Sclerosis Group's Specialised Register (3 March 2011). We checked references in identified trials and manually searched the reports (2004 to May 2011) from neurological associations and MS Societies in Europe and America. We also communicated with researchers who were participating in trials on rituximab and contacted Genentech, BiogenIdec, Roche. Selection criteria All randomised double-blind controlled parallel clinical trials with a length of follow-up >= one year, evaluating rituximab, alone or as add-on with other therapies, versus placebo, or any other treatment for patients with RR-MS, without restrictions regarding dosage, administration frequency and duration of treatment. Titles and abstracts of the citations retrieved by the literature search were screened independently for inclusion/exclusion by two review authors. Any disagreement regarding inclusion was resolved by discussion, or by referral to a third assessor if necessary. Data collection and analysis Two review authors independently assessed trial quality and extracted data. Disagreements were discussed and resolved by consensus among review authors. Principal investigators of included studies were contacted for additional data or confirmation. Main results One trial involving 104 adult RR MS patients with an entry score <= 5.0 EDSS and at least one relapse during the preceding year was included. This trial evaluated rituximab alone versus placebo with a single course of rituximab (on day 1 and 15). Treated patients had a lower rate of relapse at 24 weeks but not at 48 weeks. The MRI data were available only at 24 weeks. A significant attrition bias was found at 48 week (40.0% in the placebo group and 15.9% in the rituximab group). Mild-to-moderate infusion-associated adverse events within 24 hours after the first rituximab infusion occurred in the rituximab group. Authors' conclusions We are unable to give any clear recommendations for the use of rituximab as a therapy for RR-MS. The beneficial effects of rituximab for RR-MS remain inconclusive because of the high attrition bias, the small number of participants and the short follow-up. However, short-term treatment with a single course of rituximab resulted to be safe for most patients with RR-MS. The potential benefits of rituximab for treating RR-MS need to be evaluated in large scale studies along with long-term safety. Disability progression and quality of life should be addressed in future research.

Tailoring B cell depletion therapy in MS according to memory B cell monitoring

Rituximab As Maintenance Therapy Following Remission Induction in Relapsing or Refractory Systemic Lupus Erythematosus.

Tailoring Rituximab According to CD27-Positive B-Cell versus CD19-Positive B-Cell Monitoring in Neuromyelitis Optica Spectrum Disorder and MOG-Associated Disease: Results from a Single-Center Study

B-cell proliferation characteristics and monitoring significance under the modified reduced-dose rituximab regimen for NMOSD: A real-world case series study

Repeated iv anti‐CD20 treatment in multiple sclerosis: Long‐term effects on peripheral immune cell subsets

Efficacy and Safety of Repeated Low-Dose Rituximab Therapy in Relapsing-Remitting Multiple Sclerosis: A Retrospective Case Series Study.

Assessing Sustained B-Cell Depletion and Disease Activity in a French Multiple Sclerosis Cohort Treated by Long-Term IV Anti-CD20 Antibody Therapy

Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis

Is Low Threshold of B Cells an Obligatory Monitoring Indicator of Repeated RTX Infusion in the Treatment of Neuromyelitis Optica Spectrum Disorder? – A Report of Two Cases

Effect of Different Initial Rituximab Regimens on B Cell Depletion in Children with Autoimmune Neurological Diseases.

Rituximab for relapsing-remitting multiple sclerosis

Rituximab, Use and B Cell Depletion in Patients with Membranous Nephropathy- A Retrospective, Observational Study

Impact of treatment on cellular immunophenotype in MS: A cross-sectional study

Rituximab in secondary progressive multiple sclerosis: a meta‐analysis

B cell repopulation trajectory after rituximab treatment in autoimmune diseases: a longitudinal observational study

A Real-World Experience of Rituximab: A Panacea in Therapy of Multiple Sclerosis in Low- and Middle-Income Setting

Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder

Cladribine tablets in Relapsing-Remitting Multiple Sclerosis preferentially target B-cells

Rituximab at lower dose for neuromyelitis optica spectrum disorder: a multicenter, open-label, self-controlled, prospective follow-up study

NK Cell Levels Correlate with Disease Activity in Patients with Multiple Sclerosis on Ocrelizumab/Rituximab Therapy

COMBAT‐MS: A Population‐Based Observational Cohort Study Addressing the Benefit–Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab